Condition
Myasthenia Gravis, Ocular
Total Trials
6
Recruiting
3
Active
4
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 3 (2)
Trial Status
Recruiting3
Completed2
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07249632Phase 3RecruitingPrimary
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
NCT06558279Phase 3Active Not RecruitingPrimary
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06617741Recruiting
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT05214612Recruiting
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
NCT05380128CompletedPrimary
Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population
NCT03049956Not ApplicableCompletedPrimary
OVEMP in Myasthenia
Showing all 6 trials